Medical Consultant, Department of Cornea and Refractive Surgery, Aravind Eye Hospital, Salem, Tamil Nadu, India.
Comprhensive Ophthalmology Fellow, Aravind Eye Hospital, Salem, Tamil Nadu, India.
Indian J Ophthalmol. 2019 Sep;67(9):1400-1404. doi: 10.4103/ijo.IJO_2112_18.
With increasing environmental pollution, the incidence of allergic conjunctivitis is increasing. Newer anti-allergic medications with combined anti-histaminic and mast cell stabilization action can help reducing the use of topical steroids for milder form of disease. There is no study directly comparing olopatadine (0.1%), bepotastine (1.5%), and alcaftadine (0.25%) for mild to moderate allergic conjunctivitis cases. Hence, we decided to methodically study the efficacy of three topical medications.
Prospective, observer-masked clinical trial enrolled 45 patients with 15 patients in each of the three groups. Patients with mild to moderate allergic conjunctivitis were sequentially assigned to respective groups, and relief of symptoms and signs were noted upto 1-month follow-up.
All three topical medications faired almost equally in resolving symptoms of the patients with mild to moderate allergic conjunctivitis, and most of them reported complete relief after 1 week of use of medication. Few cases with limbal or palpebral papillae reported symptomatic relief after use of medication, but the resolution of these signs was not noted in all three groups.
We concluded similar efficacy of three medications in relieving symptoms and inefficacy in regressing palpebral and limbal papillae in cases of allergic conjunctivitis.
随着环境污染的增加，过敏性结膜炎的发病率正在上升。具有联合抗组胺和肥大细胞稳定作用的新型抗过敏药物可以帮助减少轻度疾病的局部类固醇使用。目前尚无直接比较奥洛他定（0.1％）、贝他斯汀（1.5％）和阿伐斯汀（0.25％）治疗轻度至中度过敏性结膜炎病例的研究。因此，我们决定系统地研究三种局部用药的疗效。
前瞻性、观察者盲法临床试验纳入了 45 名轻度至中度过敏性结膜炎患者，每组 15 名患者。将轻度至中度过敏性结膜炎患者按顺序分配到各个组中，并在 1 个月的随访中记录症状和体征的缓解情况。
三种局部用药在缓解轻度至中度过敏性结膜炎患者的症状方面效果几乎相同，大多数患者在使用药物 1 周后报告完全缓解。少数患有角膜缘或睑板乳头的患者在使用药物后报告有症状缓解，但并非所有三组患者都观察到这些体征的消退。
我们得出结论，三种药物在缓解症状方面的疗效相似，在治疗过敏性结膜炎的睑板和角膜缘乳头方面均无效。
